|
Merrimack Pharmaceuticals Inc. |
|
|
One Kendall Square, Building 700, 2nd Fl
Cambridge, MA 02139 USA
phone:617-441-1000
fax:617-491-1386
|
|
| Symbol |
Private |
| Exchange |
|
| Founded |
0 |
| Employees |
|
|
|
| www.merrimackpharma.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Medicines for the treatment of autoimmune disease and cancer |
|
| Management |
| Robert J. Mulroy, President & Chief Executive Officer; Ulrik B. Nielsen, Ph.D., Vice President of Research; Fazal Khan, Ph.D., Vice President of Manufacturing |
| |
|
|
| |
|
| Keywords |
| cancer, autoimmune disease, rheumatoid arthritis, arthritis, psoriasis |
|
|
|
| Description |
|
Merrimack is developing innovative therapies for the treatment of autoimmune disease and cancer. |
|
| Products / Services |
The company's lead product, MM-093, is currently in Phase 2 clinical trials for the treatment of patients with rheumatoid arthritis and psoriasis.
|
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members